Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys.
about
Atypical hemolytic uremic syndromeComplement cascade and kidney transplantation: The rediscovery of an ancient enemyDe novo glomerular diseases after renal transplantationEverolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.Thrombotic microangiopathy after kidney transplantation.Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient.Sirolimus in pediatric renal transplantation.A clinicopathologic study of thrombotic microangiopathy in IgA nephropathySuccessful sirolimus rescue in tacrolimus-induced thrombotic microangiopathy after living-related liver transplantation.Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome.Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients.Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathyDrug-induced thrombotic microangiopathy: a systematic review of published reports.Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy.[Thrombotic microangiopathy : Relevant new aspects for intensive care physicians].Proteinuria and baseline renal function predict mortality and renal outcomes after sirolimus therapy in liver transplantation recipients.Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations.Complement related kidney diseases: Recurrence after transplantation.Everolimus: preventing organ rejection in adult kidney transplant recipients.Drug-induced thrombosis: an update.Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?Diagnostic approach to microangiopathic hemolytic disorders.Belatacept As an Alternative to Calcineurin Inhibitors in Patients with Solid Organ Transplants.Impaired Neovascularization and Reduced Capillary Supply in the Malignant vs. Non-malignant Course of Experimental Renovascular HypertensionInhibition of MTOR disrupts autophagic flux in podocytes.Renal cortical necrosis in a renal transplant recipientEnterococcus raffinosus infection with atypical hemolytic uremic syndrome in a multiple myeloma patient after autologous stem cell transplant.Prediction of veno-occlusive disease using biomarkers of endothelial injury.Conversion from calcineurin inhibitors to mTOR inhibitors stabilizes diabetic and hypertensive nephropathy after liver transplant.Sirolimus interacts with pathways essential for podocyte integrity.Everolimus-induced nephrotic syndrome precipitated by interaction with voriconazole in a patient with Hodgkin's lymphoma.Effective immunosuppressive management with belatacept and eculizumab in post-transplant aHUS due to a homozygous deletion of CFHR1/CFHR3 and the presence of CFH antibodies.Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy.A case of atypical hemolytic uremic syndrome in a second renal transplant.Opana ER (Oxymorphone)-Induced Thrombotic Microangiopathy: An Atypical Presentation in a Patient With Hepatitis C.Summary of the 2018 ISN Frontiers Meeting: Kidney Disease and Cardiovascular Disease.Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney TransplantationThrombotic microangiopathy after renal transplantation: Current insights in and recurrent diseaseDrug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians
P2860
Q21202864-FA0D8103-299F-49DB-A612-6887875CAB79Q26829790-1412ECA2-304E-40EF-AC30-7A65CCA1C013Q27005877-69CC412F-F7F0-486C-B95F-CFC5DA965362Q33251433-E05EE51B-8770-4AB9-8898-76B73A55E262Q33372586-B409D529-8324-44B0-B6A0-81EA8F13A8C8Q33389749-AAF340DB-7451-4F95-8F2B-98CB4B0CF575Q33397668-4D57B72D-5FB9-46E5-99BA-D9E58F1CDB36Q33397974-C1D8559A-E93D-4AF1-AA2B-F6923307BD18Q33398042-E096A859-1B42-42DA-AD1A-CBD04E133DFCQ33405522-8089D0D6-C2AC-4ACE-B5EC-9806811208F6Q33409586-BED0B2DD-891B-4A16-A39E-5FEFDCC05199Q33411321-43603370-6821-40F0-8DAF-0D4DBD5369C8Q33418784-579640C5-2BE4-42F2-9D00-B7FCDF0BF15AQ33424902-E2F4FABB-714D-4091-9E76-D574FD98B4FBQ33432677-4DE87E20-28C1-44DA-83CF-DD9C1FB391F7Q33587143-7B400027-89BF-4E7F-9C31-31FE222E25C3Q37001941-1E427988-88A4-463D-9481-C18A70E371FDQ37322141-CCE7F053-400C-4FDB-91D9-4A865538CF64Q37522557-DEE4FA4D-7D69-4CFC-8C33-5FFEE47763FFQ37992135-418A0558-E37F-4106-AC35-4E1FC0EB14D6Q38103820-74090F82-9760-4E94-80B7-E592BC24F3D0Q38458152-69D108BE-7EF1-4F23-A86A-A349C0D53EA4Q39266338-64D2AA61-3E83-4DF3-85BC-C2A3407F5E91Q39350215-E3500587-36D9-49C9-997E-B0A1EEABB747Q40969480-2F776756-1BA2-4C35-9AE4-8040C04C1F7BQ41812610-D9C4D152-415B-4D1D-A347-7764DFC15DE5Q41820157-CFA3A66B-D6DE-4FDB-A5F0-DFAC9DB8B3ADQ42699958-54C49F5A-93C3-4B9F-9141-E0883D60E1DEQ42737854-6749B403-6026-40E2-8CE8-540DB70240C4Q43200374-1EDF753C-CEE5-44C3-A42F-7D45E88452ABQ45151652-FE986CBA-858F-4FF8-BF0A-E6DB4BA91318Q46182457-B439CA49-3857-41A7-BDE9-A7400A6CE5D1Q47096270-FE7F4CF8-7366-4F6A-8A23-61AD221420C4Q47912606-AFE4A88B-667D-4E90-9C52-442BFBBB60AEQ48209875-F0E2FEAD-81F4-4609-8121-B82617933014Q50052142-10EACEAB-81A6-425C-B123-25A7934A2BB3Q55476169-AA2FEE21-9762-426C-8649-0ABC08366620Q57151742-9C7E7E26-42BA-4C2E-A057-99669955D6F0Q58754943-4E7FF207-DF0D-4D64-ADE1-9A6EEFDB40FDQ58805821-AD0BCEC2-E7C4-4F91-B345-D8209764D75A
P2860
Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Sirolimus-induced thrombotic m ...... lial growth factor in kidneys.
@en
Sirolimus-induced thrombotic m ...... lial growth factor in kidneys.
@nl
type
label
Sirolimus-induced thrombotic m ...... lial growth factor in kidneys.
@en
Sirolimus-induced thrombotic m ...... lial growth factor in kidneys.
@nl
prefLabel
Sirolimus-induced thrombotic m ...... lial growth factor in kidneys.
@en
Sirolimus-induced thrombotic m ...... lial growth factor in kidneys.
@nl
P2093
P2860
P1476
Sirolimus-induced thrombotic m ...... lial growth factor in kidneys.
@en
P2093
Eymeric Lagonotte
Fouad Fadel
Hervé Sartelet
Jacques Chanard
Laure Hélène Noel
Marianne Lorenzato
Olivier Toupance
Philippe Birembaut
Philippe Rieu
P2860
P304
P356
10.1111/J.1600-6143.2005.01047.X
P407
P577
2005-10-01T00:00:00Z